Laura Kummer
A5110588403- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Peripheral Neuropathies and Disorders
- Multiple Sclerosis Research Studies
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- Heparin-Induced Thrombocytopenia and Thrombosis
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Agricultural and Food Sciences
- Vaccine Coverage and Hesitancy
- Cardiac, Anesthesia and Surgical Outcomes
- Viral Infections and Immunology Research
- Dermatological and COVID-19 studies
- Atherosclerosis and Cardiovascular Diseases
- Cancer Immunotherapy and Biomarkers
- Cell Image Analysis Techniques
- Heme Oxygenase-1 and Carbon Monoxide
- vaccines and immunoinformatics approaches
- Eicosanoids and Hypertension Pharmacology
- Autoimmune Bullous Skin Diseases
- Allergic Rhinitis and Sensitization
- Autoimmune and Inflammatory Disorders Research
- RNA Interference and Gene Delivery
Sanquin
2021-2025
Amsterdam University Medical Centers
2021-2025
Amsterdam Neuroscience
2021-2025
University of Amsterdam
2021-2025
Heidelberg University
2018-2025
University Hospital Heidelberg
2018-2025
Amsterdam UMC Location University of Amsterdam
2022-2024
Universidade Estadual do Oeste do Paraná
2022-2024
Peter Doherty Institute
2022
The University of Melbourne
2022
Chimeric antigen receptor (CAR) T cell therapy has been successful in clinical trials against hematological cancers, but experienced challenges the treatment of solid tumors. One main difficulties lies a paucity tumor-specific targets that can serve as CAR recognition domains. We therefore focused on developing VHH-based, single-domain antibody (nanobody) cells target aspects tumor microenvironment conserved across multiple cancer types. Many tumors evade immune through expression checkpoint...
Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who often treated immunosuppressive drugs. We aimed to investigate the effect different drugs antibody development after vaccination diseases.In this study, we used serum samples collected from diseases and healthy controls were included two ongoing prospective cohort studies Netherlands. Participants eligible for inclusion substudy if they had been vaccinated any vaccine via Dutch national...
Existing literature suggests that patients with autoimmune diseases might be at increased risk of developing severe COVID-19,1Gianfrancesco M Hyrich KL Al-Adely S et al.Characteristics associated hospitalisation for COVID-19 in people rheumatic disease: data from the Global Rheumatology Alliance physician-reported registry.Ann Rheum Dis. 2020; 79: 859-866Crossref PubMed Scopus (911) Google Scholar which emphasises importance vaccination against SARS-CoV-2 this patient group. However, vaccine...
To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated ocrelizumab or fingolimod.This is substudy of prospective multicenter study SARS-CoV-2 immune-mediated diseases. Patients MS ocrelizumab, fingolimod, and no disease-modifying therapies healthy controls were included. The number interferon (IFN)-γ secreting SARS-CoV-2-specific T cells at time points before...
Studies have suggested incremental short-term adverse events (AE) after repeated vaccination. In this report, we assessed occurrence and risk factors for AEs following SARS-CoV-2 vaccination in patients with various immune-mediated inflammatory diseases (IMIDs).
Abstract During the COVID‐19 pandemic, daily life of many patients with dermatological immune‐mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused (fear of) morbidity, mortality associated COVID‐19, vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored impact disease vaccination on DIMIDs, specifically AD, vitiligo. Data from DIMIDs were collected part...
Patients affected by different types of autoimmune diseases, including common conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated with immunosuppressants to suppress disease activity. It is not fully understood how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral cellular immunity induced infection and/or upon vaccination immunosuppressants.The dynamics immune reactivation SARS-CoV-2 experienced MS patients humanized...
Objectives To compare the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants controls, to investigate determinants for infections. Methods Data were used from an ongoing national prospective multicentre cohort study vaccination responses in IMID Netherlands (Target-to-B! (T2B!) study). Patients wih controls (patients not healthy controls) who completed...
SARS-CoV-2-specific CD8
Background Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated ocrelizumab (OCR), a B cell-depleting anti-CD20 monoclonal antibody, is not yet fully understood. Methods In this study, deep immune profiling techniques were employed to investigate the response induced by mRNA untreated MS (n=21), OCR-treated (n=57) and individuals (n=30). Results Among MS, 63% did...
Background Research on the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term prospective data development SARS-CoV-2 antibodies these are lacking. Methods Adult IMIDs from Amsterdam Rheumatology Immunology Center, were invited to participate. All asked recruit their own sex-matched age-matched control subject. Clinical collected via online questionnaires (at baseline, after 1–4 5–9 months follow-up)....
Abstract Background The noninflammatory immunoglobulin G4 (IgG4) is linked to tolerance and unique humans. Although poorly understood, prolonged antigenic stimulation IL‐4‐signaling along the T helper 2‐axis may be instrumental in IgG4 class switching. Recently, repeated SARS‐CoV‐2 mRNA vaccination has been skewing. widely used immunosuppressive drugs have shown only moderately affect humoral responses vaccination, effect on switching not investigated. Methods Here we study impact of such...
The objective of this study was to measure humoral responses after SARS-CoV-2 vaccination in MS patients treated with ocrelizumab (OCR) compared without disease modifying therapies (DMTs) relation timing and B-cell count.OCR were divided into an early a late group (cut-off time 12 weeks between infusion first vaccination). Patients vaccinated mRNA-1273 (Moderna). B-cells measured at baseline (time vaccination) antibodies baseline, day 28, 42, 52 70.87 included (62 OCR patients, 29 DMTs). At...
Gene therapeutic approaches to aortic diseases require efficient vectors and delivery systems for transduction of endothelial cells (ECs) smooth muscle (SMCs). Here, we developed a novel strategy efficiently deliver previously described vascular-specific adeno-associated viral (AAV) vector the abdominal aorta by application alginate hydrogels. To transduce ECs SMCs, used AAV9 with modified capsid (AAV9SLR) encoding enhanced green fluorescent protein (EGFP), as wild-type AAV do not SMCs well....
It is unclear which patients with multiple sclerosis (MS) are most susceptible for omicron breakthrough infections.We assessed infections in vaccinated MS and without disease-modifying therapies enrolled an ongoing large prospective study. We longitudinally studied humoral responses after primary booster vaccinations infections.Omicron were reported 110/312 (36%) MS, 105/110 (96%) mild. Omicron occurred more frequently treated anti-CD20 sphingosine-1 phosphate receptor (S1PR) modulators,...
Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time vaccination could predict response SARS-CoV-2 vaccination. In 52 MS, we found be a good predictor for IgG anti-RBD titers (comparable B-cell count). As course may predicted using pharmacokinetic models,...
Abstract Background Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate against a primary infection in unvaccinated IMID patients ISPs. Methods active treatment ISPs controls (i.e. not ISP healthy controls) confirmed before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical...
BACKGROUND: Perioperative major adverse cardiovascular and cerebrovascular events (MACCEs) are incompletely understood, risk prediction is imprecise. Atherogenic leukocytes crucial in events. However, it unclear if surgical interventions affect leukocyte counts or activation status. Therefore, we investigated whether noncardiac surgery patients with elevated associated changes atherogenic subsets these related to perioperative MACCEs. METHODS: We enrolled 40 this single-center prospective...